Lead from the frontline: Optimizing first-line treatment selection in Ph+ ALL

Welcome to this EBAC-accredited symposium from the 2023 ASCO^® Annual Meeting where Dr Elias Jabbour, Dr Hagop Kantarjian and Dr Nicholas Short discuss frontline treatment options for Ph+ ALL. Before watching this symposium, test your knowledge on the topics covered in the session by answering the quiz questions below. To gain 1 CME credit, watch the entire session and complete the final knowledge assessment and evaluation form. You will need to achieve a score of 4/6 on the knowledge assessment to receive your CME credit.

Case study questions - when the case studies present in the symposium video, follow along as Dr Elias Jabbour discusses the Ph+ ALL patient case studies and test your knowledge below:

This programme is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 1 hour of external CME credit. Each participant should claim only those hours of credit that have actually been spent in the educational activity.

Learning objectives

After participating in this educational activity, you will be able to:

• Recall frontline treatment approaches for Ph+ ALL
• State best practice recommendations for the implementation of MRD assessment to guide disease management in Ph+ ALL
• Describe the impact of T315I mutations on treatment resistance in Ph+ ALL
• Identify risk factors for relapse in Ph+ ALL

Target audience

This activity has been designed to meet the educational needs of hematologic and general oncologists, as well as nurses, advanced practitioners and pharmacists in contact with patients with Ph+ ALL.

Elias Jabbour, MD (Chair)

Dr Jabbour joined the MD Anderson Cancer Center faculty in 2007 and is currently a Professor of Medicine in the Department of Leukemia. He is actively involved in developmental therapeutics research in leukaemia.

Over the past 5 years, Dr Jabbour has assisted in developing chemotherapeutic and biologic agents in leukaemia and has contributed to the development of others, including the Hyper CVAD-ofatumumab regimen in ALL, clofarabine in myeloid malignancies, hypomethylating agents in acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS), tyrosine kinase therapy in chronic myeloid leukaemia (CML), and triple therapy in AML.

Dr Jabbour has authored or co-authored hundreds of peer-reviewed medical publications and has served on the editorial boards of several scientific journals.

Hagop Kantarjian, MD

Dr Kantarjian joined the MD Anderson Cancer Center faculty after a haematology-oncology fellowship at MD Anderson in 1981–1983, becoming Professor of Medicine in 1993. In 1995, he was named Chair of the Department of Leukemia and currently holds the Samsung Distinguished University Chair in Cancer Medicine.

Dr Kantarjian is known for his practice-changing clinical-translational research in leukaemia. Over the past four decades, his research has transformed some standards of care and dramatically improved survival in several leukaemia subtypes, including ALL, CML, AML, and MDS.

Dr Kantarjian has published more than 2,200 peer-reviewed manuscripts and more than 100 chapters. He is the Senior Editor of the four editions of the “MD Anderson Manual of Medical Oncology.” In 2000, he created the MD Anderson Leukemia Fellowship, which now trains about 10 fellows in leukaemia annually, and he is heavily involved in mentoring and education. In 2012, he co-founded the Society of Hematologic Oncology (SOHO), which has now expanded worldwide. He is a non-resident fellow in healthcare at the Rice Baker Institute and has written extensively on important healthcare issues in cancer, including high cancer drug prices; the importance of universal equitable healthcare; healthcare safety nets and healthcare as a human right; drug shortages; and the value of the Affordable Care Act.

Nicholas Short, MD

Dr. Nicholas Short is an Assistant Professor in the Department of Leukemia at the MD Anderson Cancer Center. Dr. Short is a clinical and translational investigator in adult leukemias, with a particular emphasis on measurable residual disease (MRD) and the development of Phase 1 and 2 clinical trials of novel agents and combinations for patients with acute leukemias.

Dr. Short has authored over 125 peer-reviewed manuscripts and numerous abstracts that have been presented at national and international conferences, including the American Society of Hematology (ASH) Annual Meeting and Exposition, and the American Society of Clinical Oncology (ASCO) Annual Meeting.

For his accomplishments in the field of leukemia research, he has received a number of awards, including the ASCO Young Investigator Award and the ASH Junior Faculty Scholar Award in Clinical Research.

Disclosures

Elias Jabbour, MD, disclosures: Employee or independent contractor relationship with Adaptive Biotechnologies, Amgen, Astellas Pharma Inc., BeiGene, Novartis, Pfizer Inc., Sanofi, and Takeda. Consultant relationship with GSK, NKARTA, Pfizer Inc., and Sanofi. Grants or research support from Astellas Pharma Inc., NextCure, Stemline Therapeutics, Takeda Oncology, and Xencor

Hagop Kantarjian, MD, disclosures: Grants from AbbVie, Amgen, Ascentage, Bristol Myers Squibb, Daiichi Sankyo, ImmunoGen, Jazz, Novartis, and Pfizer. Honoraria from AbbVie, Amgen, Aptitude Health, Ascentage, Astellas Health, AstraZeneca, Ipsen Biopharmaceuticals, KAHR Medical Ltd, NOVA Research, Novartis, Pfizer Inc., Precision BioSciences, and Taiho Pharma

Nicholas Short, MD, disclosures: Consultant for Pfizer Inc., Jazz Pharmaceuticals, and Sanofi. Research grants from Takeda Oncology, Astellas Pharma Inc., Xencor, and Stemline Therapeutics. Honoraria from Novartis, Amgen, Astellas Pharma Inc., Sanofi, and BeiGene.

In compliance with EBAC guidelines, all speakers/ chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organizing Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.